Halozyme Therapeutics Shares Down 11.32% Following Release Of SWOG Abstract Suggesting The Co's PEGPH20 In Combination With mFFOX Shows No Beneift And Appears To Be Detrimental; Hearing Deutsche Bank Lowered Price Target From $21 to $19 In Response